Mafosfamide
{{Chembox new
|ImageFile=Mafosfamide.svg
|ImageSize=
|IUPACName=2-{[2-[bis(2-chloroethyl)amino]-2-oxo-
1-oxa-3-aza-2λ5-phosphacyclohex-
4-yl}sulfanyl]ethanesulfonic acid
|OtherNames=
|Section1= ! colspan=2 style=”background: #f8eaba; text-align: center;” |Identifiers
|-
|
|
|-
|
|
|-
| ECHA InfoCard | Lua error in Module:Wikidata at line 879: attempt to index field ‘wikibase’ (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field ‘wikibase’ (a nil value). |-
| MeSH | Mafosfamide |-
|
|
|-
| colspan=”2″ |
- C1COP(=O)(NC1SCCS(=O)(=O)O)N(CCCl)CCCl
|- |Section2= ! colspan=2 style=”background: #f8eaba; text-align: center;” |Properties
|-
|
| C9H19Cl2N2O5PS2
|- | Molar mass
| 401.269 g/mol
|- |Section3= }}’
Overview
Mafosfamide (INN) is an oxazaphosphorine (cyclophosphamide-like) alkylating agent under investigation as a chemotherapeutic. Several Phase I trials have been completed.[1][2]
References
- ↑ “Intrathecal Mafosfamide”. ClinicalTrials.gov. U.S. National Institutes of Health. August 21 2006. Retrieved 2007-07-13. Check date values in:
|date=(help) ClinicalTrials.gov Identifier NCT00062881. - ↑ “Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors”. ClinicalTrials.gov. U.S. National Institutes of Health. February 20 2007. Retrieved 2007-07-13. Check date values in:
|date=(help) ClinicalTrials.gov Identifier NCT00031928.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH